|
|
|
04-21
|
Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine |
III |
Signal Transduction Inhibitor |
rigosertib |
|
709
|
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
III |
Bone Marrow Transplant / Stem Cell Transplant, Chemotherapy |
fludarabine; busulfan; melphalan; cyclophosphamide |
|
UPCC 15411
|
A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia |
I / II |
Biological Therapy |
birinapant |
|
UPCC 24412
|
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy |
I |
Immunotherapy |
BMS-936558 |